Aura Biosciences (AURA) Non-Current Assets (2020 - 2026)
Aura Biosciences' (AURA) quarterly Non-Current Assets came in at $19.2 million in Q1 2026, down 8.19% YoY from $20.9 million in Q1 2025, and down 2.63% on a QoQ basis from $19.7 million in Q4 2025.
Aura Biosciences (AURA) Non-Current Assets (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Non-Current Assets data on file, last reported at $19.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 8.19% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.2 million (down 9.28% YoY) and the FY2025 annual result came in at $19.7 million, down 10.0% from the prior year.
- Non-Current Assets retreated to $19.2 million in Q1 2026, from $19.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $27.2 million in Q3 2022 to a low of $6.8 million in Q1 2022.
- A 5-year average of $21.2 million and a median of $21.9 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 330.49% — and 2024, when it fell 15.53%.
- Tracing AURA's Non-Current Assets over 5 years: stood at $27.2 million in 2022, then fell by 14.51% to $23.3 million in 2023, then dropped by 6.02% to $21.9 million in 2024, then slipped by 10.0% to $19.7 million in 2025, then decreased by 2.63% to $19.2 million in 2026.
- The last three Non-Current Assets figures came in at $19.2 million (Q1 2026), $19.7 million (Q4 2025), and $19.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 19.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.10 Mn |
| Mar 31, 2026 | 19.17 Mn |
| Dec 31, 2025 | 19.69 Mn |
| Sep 30, 2025 | 19.90 Mn |
| Jun 30, 2025 | 20.44 Mn |
| Mar 31, 2025 | 20.88 Mn |
| Dec 31, 2024 | 21.88 Mn |
| Sep 30, 2024 | 21.86 Mn |
| Jun 30, 2024 | 22.69 Mn |
| Mar 31, 2024 | 22.78 Mn |
| Dec 31, 2023 | 23.28 Mn |
| Sep 30, 2023 | 25.88 Mn |
| Jun 30, 2023 | 26.53 Mn |
| Mar 31, 2023 | 26.90 Mn |
| Dec 31, 2022 | 27.23 Mn |
| Sep 30, 2022 | 27.24 Mn |
| Jun 30, 2022 | 7.35 Mn |
| Mar 31, 2022 | 6.84 Mn |
| Dec 31, 2021 | 6.33 Mn |
| Sep 30, 2021 | 7.25 Mn |